Ertugliflozin pidolate is an antidiabetic agent and a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with… Read more
Ertugliflozin pidolate is an antidiabetic agent and a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal renal tubules, this compound reduces the renal reabsorption of glucose, thereby increasing its urinary excretion to lower plasma glucose levels. To support the rigorous demands of pharmaceutical research and manufacturing, this category offers essential analytical tools including reference standards, known impurities, degradation products, and stable isotope-labelled compounds. These high-quality materials are critical for laboratories performing impurity profiling, method validation, and routine quality control analysis. By utilizing these precise standards, researchers can ensure compliance with regulatory requirements and maintain the accuracy of stability-indicating assays throughout the drug development and manufacturing lifecycle.